CHEETAH MEDICAL, INC.
NEWTON CENTER, MA

The company was founded in Israel in the early 2000’s with the mission of helping clinicians manage their patient’s fluid status. Currently headquartered in Boston, Massachusetts, Cheetah also has offices in Tel Aviv, Israel and Vancouver, Washington. Cheetah sells through a direct sales organization in the US while utilizing a network of distributors to reach 25+ countries outside the US. About Cheetah Medical’s Technology systems use a proprietary algorithm to calculate hemodynamic parameters to assess heart function. Medical professionals use this information to assess patients’ unique volume requirements to maintain optimal fluid volume and perfuse critical organs. Cheetah Medical technologies are designed to enable more confident and informed treatment decisions that support the clinical goals of improving patient outcomes and driving economic efficiencies. Chris Hutchison joined Cheetah Medical in March, 2013. He brings with him over 25 years’ experience in the medical device industry and extensive global management experience, successfully commercializing mature and early stage technologies in the US, Europe and emerging markets. Prior to Cheetah, he spent seven years with Covidien, serving as president of the European Respiratory and Monitoring Division, then leading the European Vascular Therapies Division before returning to manage the integration of Covidien’s $2.6 billion acquisition of ev3. Chris then managed all of Covidien’s vascular business outside the US. Before Covidien, he served as president of Smiths Medical’s US Anesthesia Division. Kevin McArdle has served as our chief financial officer since May 2015. From January 2009 to May 2015, Mr. McArdle was the Chief Financial Officer of Histogenics Corporation, a clinical stage company focused on the regeneration and treatment of articular cartilage defects, where he led the company through its initial public offering on NASDAQ (HSGX) in 2014. Prior to joining Histogenics, Mr. McArdle was contract chief financial officer for two life science companies, Avedro, Inc. and INVO Bioscience, Inc., from January 2007 to January 2009. During this time, Mr. McArdle also started two seed-stage technologies of his own in the fields of cardiac resynchronization therapy (Oxus Medical) and orthopedics (Tesa Medical). Mr. McArdle was vice president of worldwide finance for Microsulis, an international, commercial-stage company focused on ablation of unhealthy tissue for endometriosis, liver cancer and venous malformations from 2004 to 2007. From 1998 to 2004, Mr. McArdle was employed by BioSphere Medical. Mr. McArdle received his BS and MBA from Boston College. As GM and CTO of Cheetah Medical for the past nine years, Mr. Levy led the efforts to successfully convert the Cheetah Medical flag product from the prototype phase to a fully commercialized medical monitor, managing the processes from product conception to product realization. Prior to joining Cheetah, Mr. Levy was co-founder and CTO of Intellmedix LTD, a startup company focusing on the development of web-based EMR systems for clinics and hospitals. Prior to IntellMedix, Mr. Levy held different positions in WideMed LTD, a public company which developed a clinical sleep information system and CHF screening system based on sleep medicine parameters. Mr. Levy holds a BSc in electrical engineering from Ben-Gurion University and an MBA from Bar-Ilan University’s Executive MBA program. Shane Cooke joined Cheetah Medical in June 2014 as the Vice President of Marketing, Strategy & Business Development. Based in the Boston area, he has over 15 years of experience in the medical device and pharmaceutical market spaces in a variety of sales, marketing, strategy and portfolio management roles. Prior to Cheetah, Shane spent 11 years with Covidien in the patient care, vascular therapies and corporate sectors, with positions such as: corporate strategy, market and competitive intelligence, leading the market development center of excellence and leading strategy efforts for Japan, Europe, Australia and Canada. Shane holds a BA in psychology from the University of Rochester, as well as an MBA from Suffolk University. Doug Hansell: Chief Physician Executive Doug Hansell joined Cheetah in December 2014 as the chief physician executive. He joined Cheetah from GE Healthcare ($18B) where he served as chief medical officer for four years. Prior to joining GE, Dr. Hansell was chief medical officer in the respiratory and patient monitoring business unit at Covidien. In the early 2000’s, Dr. Hansell worked in both early-stage biotech and early-stage venture capital. Dr. Hansell was chief medical officer of Emerson Health System in the late 90’s. Dr. Hansell is boarded in both internal medicine and anesthesiology and he continues to hold clinical and teaching appointments at Massachusetts General Hospital and Harvard University. Dr. Hansell attended the University of Illinois and Harvard University. Philip is vice president of sales & national accounts and is based in the NY metro area. Prior to joining Cheetah, Philip held a variety of senior-level commercial roles at Smiths Medical, ranging from: VP of global sales and marketing for business development, OEM and animal health business units – VP global integrated business planning, demand management and sales operations – VP of sales. Philip holds a master’s in business administration (MBA) and bachelor of science (BS) in marketing and business management from the business school of Manhattan College in New York. Agnes joined Cheetah Medical in June 2015 as the EMEA & APAC sale director. Agnes has over 20 years’ experience in the healthcare industry, with senior level business management roles at international scope. Prior to joining Cheetah Medical, Agnes ran the European business, as the General Manager for GE Healthcare for the anesthesia portfolio. Agnes developed her commercial skills in Covidien, where she managed the PNL for the South of Europe region for the anesthesia and monitoring ranges. She has a strong experience in international marketing, strategic and operational, as she served for three years as vice president marketing for Europe in Coviden. Prior to Covidien, Agnes ran global marketing for Sorin Group for the cardiac rhythm management portfolio. Agnes holds a master’s degree in biochemistry from University of PARIS VII and a MBA from Hayward University.